What Is 11β-hydroxylase type 1 deficiency

Overview

11β-hydroxylase type 1 deficiency is a rare form of congenital adrenal hyperplasia (CAH) caused by impaired activity of the enzyme 11β-hydroxylase, which is encoded by the CYP11B1 gene. This enzyme is essential for cortisol biosynthesis in the adrenal cortex, specifically catalyzing the conversion of 11-deoxycortisol to cortisol. When this step is disrupted, cortisol production drops, triggering increased adrenocorticotropic hormone (ACTH) secretion via feedback mechanisms, which in turn stimulates adrenal hyperplasia.

The disorder was first clinically described in 1956 by Biglieri and colleagues, who identified patients with virilization and hypertension—unusual features compared to other forms of CAH. Unlike the more common 21-hydroxylase deficiency, which affects about 95% of CAH cases, 11β-hydroxylase deficiency accounts for only 5–8% of all CAH diagnoses globally. It is inherited in an autosomal recessive pattern, meaning both parents must carry a defective copy of the gene for a child to be affected.

This condition holds significant clinical importance due to its dual presentation: androgen excess leading to ambiguous genitalia in genetic females and mineralocorticoid excess causing early-onset hypertension. These features make it one of the few CAH variants associated with high blood pressure, a distinguishing diagnostic clue. Its prevalence varies geographically, with higher rates reported in populations such as Moroccan Jews, where founder mutations in CYP11B1 have been identified.

How It Works

The biochemical pathway disrupted in 11β-hydroxylase deficiency is central to adrenal steroidogenesis. The enzyme 11β-hydroxylase, located in the mitochondria of adrenal cortical cells, normally converts 11-deoxycortisol into cortisol and deoxycorticosterone (DOC) into corticosterone. When this enzyme is deficient, both cortisol and corticosterone synthesis are impaired, leading to accumulation of precursors that drive androgen overproduction and hypertension.

• Enzyme Function: 11β-hydroxylase catalyzes the addition of a hydroxyl group at the 11-beta position of steroid molecules, a critical step in cortisol synthesis.
• CYP11B1 Gene: Located on chromosome 8q24.3, this gene spans approximately 9 kb and contains 9 exons; over 60 pathogenic mutations have been documented.
• Cortisol Deficiency: Low cortisol levels trigger increased ACTH release from the pituitary, causing adrenal gland enlargement and hyperplasia.
• Androgen Buildup: Excess 11-deoxycortisol is shunted into androgen pathways, increasing androstenedione and testosterone, leading to virilization.
• Mineralocorticoid Excess: Accumulated deoxycorticosterone (DOC) acts as a potent mineralocorticoid, promoting sodium retention and hypertension.
• Diagnostic Markers: Elevated serum 11-deoxycortisol and DOC levels, often 5–10 times higher than normal, confirm the diagnosis.
• Genetic Inheritance: Autosomal recessive; carriers have one mutated allele and are asymptomatic, while affected individuals inherit two mutated copies.

Key Details and Comparisons

The comparison highlights key diagnostic differences among adrenal enzyme deficiencies. While both 11β-hydroxylase and 21-hydroxylase deficiencies cause virilization and cortisol deficiency, only 11β-hydroxylase deficiency is associated with hypertension due to DOC accumulation. In contrast, 17α-hydroxylase deficiency causes hypertension and sexual underdevelopment but not virilization. The table underscores the importance of hormonal profiling in differential diagnosis. For example, measuring 11-deoxycortisol levels helps distinguish 11β-hydroxylase deficiency from other forms. Additionally, genetic testing for CYP11B1 mutations provides definitive confirmation, especially in ambiguous cases or prenatal diagnoses.

Real-World Examples

One well-documented case occurred in a female infant of Moroccan descent born with ambiguous genitalia and elevated blood pressure at three weeks of age. Hormonal testing revealed markedly elevated 11-deoxycortisol and DOC levels, and genetic analysis confirmed a homozygous mutation in CYP11B1 (c.853_854delCT), a known founder mutation in this population. Early diagnosis allowed prompt glucocorticoid replacement and blood pressure management, preventing long-term complications.

Another example involves a cohort study in Saudi Arabia, where researchers identified 12 patients with 11β-hydroxylase deficiency among 150 CAH cases, indicating a higher regional prevalence. These patients presented with clitoromegaly, advanced bone age, and hypertension as early as infancy. The study emphasized the need for newborn screening protocols in high-prevalence regions.

1. A 2-year-old boy with precocious puberty and hypertension diagnosed with elevated DOC and confirmed CYP11B1 mutation.
2. A prenatal diagnosis via amniocentesis in a family with a history of CAH, leading to early intervention.
3. A case in Turkey involving compound heterozygous mutations (p.R374W and p.V386A) with severe virilization.
4. A 6-month-old girl with salt-wasting symptoms initially misdiagnosed as 21-hydroxylase deficiency, later corrected via steroid profiling.

Why It Matters

Understanding 11β-hydroxylase deficiency is critical for timely diagnosis and management, as untreated cases can lead to severe developmental, cardiovascular, and psychological consequences. Early detection enables interventions that improve quality of life and prevent complications such as growth impairment and infertility.

• Impact: Early virilization in females can lead to incorrect sex assignment at birth without prompt diagnosis.
• Impact: Untreated hypertension increases the risk of left ventricular hypertrophy and stroke in childhood.
• Impact: Excess androgens cause rapid growth in childhood but premature epiphyseal closure, resulting in short adult stature.
• Impact: Psychological distress due to genital ambiguity and gender identity issues requires multidisciplinary care.
• Impact: Genetic counseling is essential for carrier families to assess recurrence risk, which is 25% per pregnancy.

In conclusion, 11β-hydroxylase type 1 deficiency, while rare, exemplifies the complexity of adrenal disorders. Its unique combination of androgen excess and hypertension necessitates a nuanced diagnostic approach. Advances in genetic testing and newborn screening offer hope for earlier detection, particularly in high-risk populations. As research continues, improved therapies and long-term outcomes are expected for affected individuals worldwide.